


Visit <http://tinyurl.com/OPPInGlaucoma> for online testing and instant CME certificate.

The Role of Ocular Perfusion Pressure in Glaucoma



Original Release Date: November 1, 2015
Last Review Date: September 22, 2015
Expiration Date: November 30, 2016

Faculty

Robert N. Weinreb, MD
Course Director and Moderator

David S. Greenfield, MD

Neeru Gupta, MD, PhD, MBA

Jeffrey Liebmann, MD

Robert Ritch, MD

Rohit Varma, MD, MPH

Jointly provided by New York Eye and Ear Infirmary of Mount Sinai
and MedEdicus LLC



MedEdicus

This continuing medical education activity is supported through an
unrestricted educational grant from Bausch & Lomb Incorporated.

Distributed with **EyeNet**
MAGAZINE
 AMERICAN ACADEMY
OF OPHTHALMOLOGY
The Eye M.D. Association

Faculty

Robert N. Weinreb, MD

Course Director and Moderator

Chairman and Distinguished Professor of Ophthalmology Director, Shiley Eye Institute Director, Hamilton Glaucoma Center University of California, San Diego La Jolla, California

David S. Greenfield, MD

Professor of Ophthalmology Bascom Palmer Eye Institute University of Miami Miller School of Medicine Palm Beach Gardens, Florida

Neeru Gupta, MD, PhD, MBA

Professor and Dorothy Pitts Chair Ophthalmology & Vision Sciences Laboratory Medicine & Pathobiology Chief of Glaucoma University of Toronto Toronto, Ontario, Canada

Jeffrey Liebmann, MD

Shirlee and Bernard Brown Professor of Ophthalmology Vice-Chair, Department of Ophthalmology Director, Glaucoma Service Columbia University Medical Center New York, New York

Robert Ritch, MD

Shelley and Steven Einhorn Distinguished Chair Professor of Ophthalmology Surgeon Director Emeritus and Chief Glaucoma Service New York Eye and Ear Infirmary of Mount Sinai New York, New York

Rohit Varma, MD, MPH

Grace and Emery Beardsley Professor and Chair Department of Ophthalmology University of Southern California (USC) Director, USC Eye Institute Associate Dean for Strategic Planning and Network Development Keck School of Medicine of USC Los Angeles, California

CME Reviewer for New York Eye and Ear Infirmary of Mount Sinai

Joseph F. Panarelli, MD

Assistant Professor of Ophthalmology Icahn School of Medicine at Mount Sinai Associate Residency Program Director New York Eye and Ear Infirmary of Mount Sinai New York, New York

Learning Method and Medium

This educational activity consists of a supplement and ten (10) study questions. The participant should, in order, read the learning objectives contained at the beginning of this supplement, read the supplement, answer all questions in the post test, and complete the Activity Evaluation/Credit Request form. To receive credit for this activity, please follow the instructions provided on the post test and Activity Evaluation/Credit Request form. This educational activity should take a maximum of 1.5 hours to complete.

Content Source

This continuing medical education (CME) activity captures content from a roundtable discussion held on May 1, 2015, in Denver, Colorado.

Activity Description

Evidence from epidemiologic studies and clinical trials alike suggests that ocular perfusion pressure (OPP) as well as other factors such as blood pressure, vasospasm, and ischemia may all contribute to glaucoma risk. The evidence and interest in the role of OPP is progressing and growing. A panel of glaucoma specialists with clinical and academic expertise in the vascular aspects of glaucoma herein present a conceptual framework for the role of OPP in glaucoma, review the evidence to support this association, and provide guidance for assessing and incorporating OPP into the evaluation and management of glaucoma patients in the office.

Target Audience

This activity intends to educate glaucoma specialists and general ophthalmologists.


Learning Objectives

Upon completion of this activity, participants will be better able to

- Outline the role of ocular perfusion pressure as a risk factor for glaucoma
- Describe the assessment of ocular perfusion pressure in patients with glaucoma

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of **New York Eye and Ear Infirmary of Mount Sinai** and **MedEdicus LLC**. The **New York Eye and Ear Infirmary of Mount Sinai** is accredited by the ACCME to provide continuing medical education for physicians.

 In July 2013, the Accreditation Council for Continuing Medical Education (ACCME) awarded New York Eye and Ear Infirmary of Mount Sinai "Accreditation with Commendation," for six years as a provider of continuing medical education for physicians, the highest accreditation status awarded by the ACCME.

AMA Credit Designation Statement

The **New York Eye and Ear Infirmary of Mount Sinai** designates this enduring material for a maximum of 1.5 **AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Grantor Statement

This continuing medical education activity is supported through an unrestricted educational grant from Bausch & Lomb Incorporated.

Disclosure Policy Statement

It is the policy of **New York Eye and Ear Infirmary of Mount Sinai** that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). **New York Eye and Ear Infirmary of Mount Sinai** has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Full disclosure of faculty/planners and their commercial relationships, if any, follows.

Disclosures

David S. Greenfield, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Consultant/Advisory Board*: Alcon, Inc; Allergan, Inc; Bausch & Lomb Incorporated; Biometric Imaging, Inc; and Senju Pharmaceutical Co, Ltd.

Neeru Gupta, MD, PhD, MBA, had a financial agreement or affiliation during the past year with the following commercial interest in the form of *Consultant/Advisory Board*: Bausch & Lomb Incorporated.

Jeffrey Liebmann, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Consultant/Advisory Board*: Alcon, Inc; Allergan, Inc; Bausch & Lomb Incorporated; Diopsys, Inc; Forsight Vision 2; Heidelberg Engineering; Merz, Inc; Sustained Nano Systems, LLC; and Valeant Pharmaceuticals International, Inc; *Grant Support*: Allergan, Inc; Bausch & Lomb Incorporated; Diopsys, Inc; Heidelberg Engineering; New York Glaucoma Research Institute; Reichert, Inc; Topcon Medical Systems, Inc; and Valeant Pharmaceuticals International, Inc; *Ownership Interest*: Diopsys, Inc; SOLX, Inc; and Sustained Nano Systems, LLC.

Robert Ritch, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Royalty*: Ocular Instruments; *Consultant/Advisory Board*: Aeon Astron Corporation; iSonic Medical; and Sensimed AG; *Honoraria from promotional, advertising, or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus)*: Aeon Astron Corporation; and Santen Pharmaceutical Co, Ltd; *Ownership Interest*: Aeon Astron Corporation; and Diopsys, Inc.

Rohit Varma, MD, MPH, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Consultant/Advisory Board*: Aerie Pharmaceuticals, Inc; AqueSys, Inc; Genentech, Inc; and Isarna Therapeutics.

Robert N. Weinreb, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Consultant/Advisory Board*: Alcon, Inc; Allergan, Inc; Bausch & Lomb Incorporated; and Valeant Pharmaceuticals International, Inc; *Contracted Research*: Aerie Pharmaceuticals, Inc; Genentech, Inc; and Quark Pharmaceuticals, Inc.

New York Eye and Ear Infirmary of Mount Sinai Peer Review Disclosure

Joseph F. Panarelli, MD, has no relevant commercial relationships to disclose.

Editorial Support Disclosures

Cheryl Guttman Krader; Cynthia Tornallyay, RD, MBA, CHCP; Diane McArdle, PhD; Kimberly Corbin, CHCP; Barbara Aubel; and **Barbara Lyon** have no relevant commercial relationships to disclose.

Disclosure Attestation

The contributing physicians listed above have attested to the following:

- 1) that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
- 2) that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
- 3) that all reasonable clinical alternatives will be discussed when making practice recommendations.

Off-Label Discussion

This activity does not include off-label discussion. Readers should consult the official prescribing information for indications and administration of all products mentioned.

For Digital Editions

System Requirements:

If you are viewing this activity online, please ensure the computer you are using meets the following requirements:

- **Operating System:** Windows or Macintosh
- **Media Viewing Requirements:** Flash Player or Adobe Reader
- **Supported Browsers:** Microsoft Internet Explorer, Firefox, Google Chrome, Safari, and Opera
- **A good Internet connection**

New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies

<http://www.nyee.edu/health-professionals/cme/enduring-activities>

CME Provider Contact Information

For questions about this activity, call 212-979-4383.

To Obtain AMA PRA Category 1 Credit™

To obtain **AMA PRA Category 1 Credit™** for this activity, read the material in its entirety and consult referenced sources as necessary. Complete the evaluation form along with the post test answer box within this supplement. Remove the Activity Evaluation/Credit Request page from the printed supplement or print the Activity Evaluation/Credit Request page from the Digital Edition. Return via mail to Kim Corbin, Director, ICME, **New York Eye and Ear Infirmary of Mount Sinai**, 310 East 14th Street, New York, NY 10003 or fax to (212) 353-5703. Your certificate will be mailed to the address you provide on the Activity Evaluation/Credit Request form. Please allow 3 weeks for Activity Evaluation/Credit Request forms to be processed. There are no fees for participating in and receiving CME credit for this activity.

Alternatively, we offer instant certificate processing and support Green CME. Please take this post test and evaluation online by going to <http://tinyurl.com/OPPinGlaucoma>. Upon passing, you will receive your certificate immediately. You must score 70% or higher to receive credit for this activity, and may take the test up to 2 times. Upon registering and successfully completing the post test, your certificate will be made available online and you can print it or file it.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of **New York Eye and Ear Infirmary of Mount Sinai**, MedEdicus LLC, Bausch & Lomb Incorporated, or EyeNet.

This CME activity is copyrighted to MedEdicus LLC ©2015. All rights reserved.

Introduction

Glaucoma is among the most common causes of irreversible vision loss worldwide. While its primary etiology remains incompletely understood, we have developed a robust understanding of the risk factors that contribute to the development and progression of the disease. Among these, intraocular pressure (IOP) remains the most important risk factor, both because of its strength of association with the disease and because it remains the only modifiable risk factor. In addition to IOP, vascular factors have long been suspected of playing a role in the glaucomatous process. Evidence from epidemiologic studies and clinical trials alike suggests that ocular perfusion pressure (OPP)—in simplest terms, the difference between IOP and systemic blood pressure (BP)—as well as other factors such as BP, vasospasm, and ischemia may all contribute to glaucoma risk. A panel of glaucoma specialists with clinical and academic expertise in the vascular aspects of glaucoma herein present a conceptual framework for the role of OPP in glaucoma, review the evidence to support this association, and provide guidance for assessing and incorporating OPP into the evaluation and management of glaucoma patients in the office.

Defining Ocular Perfusion Pressure

Dr Liebmann: Ocular perfusion pressure can be thought of as the pressure at which blood enters the eye. Mathematically, OPP is defined as the arterial BP minus IOP. Both of these determinants are dynamic biological parameters. Intraocular pressure varies throughout the day and from day to day. Blood pressure is even more variable, with significant changes throughout each cardiac cycle. During each heartbeat, systemic BP rises to a peak, the systolic BP, and then drops to a trough, the diastolic BP. Thus, OPP is also a dynamic parameter, varying as both BP and IOP vary.

Ocular perfusion pressure can be thought of as the pressure at which blood enters the eye.

—Jeffrey Liebmann, MD

Just as the complex variability of BP can be described using summary parameters—systolic, diastolic, and mean BP—the same summary parameters can be applied to OPP. Mean OPP (MPP) is the difference between mean arterial BP and IOP. Mean arterial BP is calculated using a formula (Table 1) that accounts for diastole taking up most of the cardiac cycle. Systolic OPP (SPP) and diastolic OPP (DPP) are calculated as systolic (or diastolic) BP minus IOP (Table 1).

Table 1. Definitions of Ocular Perfusion Pressure Parameters

Mean OPP (MPP)	$2/3 [\text{diastolic BP} + 1/3 (\text{systolic BP} - \text{diastolic BP})] - \text{IOP}$
Systolic OPP (SPP)	$\text{Systolic BP} - \text{IOP}$
Diastolic OPP (DPP)	$\text{Diastolic BP} - \text{IOP}$

BP=blood pressure; IOP=intraocular pressure; OPP=ocular perfusion pressure.

Clearly, OPP changes with changes in BP, IOP, or both. When BP is high and/or IOP is low, OPP is high; likewise, when BP is low and/or IOP is high, OPP is low. Because BP is significantly greater than IOP, OPP is more sensitive to changes in BP than to changes in IOP. Blood pressure in the normal range varies on the order of 40 to 60 mm Hg within each cardiac cycle, while typical circadian variations in IOP are generally on the order of 5 to 8 mm Hg. Therefore, patients with significantly elevated BP (systemic

hypertension) or those with significant dips in BP at night (nocturnal hypotension) may experience dramatic changes in OPP throughout the day.

—Jeffrey Liebmann, MD

hypertension) or those with significant dips in BP at night (nocturnal hypotension) may experience dramatic changes in OPP throughout the day.

Dr Weinreb: Mathematically, diastolic BP has a greater effect than systolic BP in calculating mean OPP.

Dr Greenfield: The formula for calculating mean OPP reveals that a 10-mm Hg change in systolic BP results in a 2.2-mm Hg change in mean OPP, while a similar 10-mm Hg change in diastolic BP produces a 4.4-mm Hg change in mean OPP.

Dr Weinreb: Likewise, the systolic and diastolic BPs have greater effect than the IOP in determining OPP. A 10-mm Hg change in either systolic or diastolic BP is likely a very common event in most people. A 10-mm Hg change in IOP, however, is likely a fairly uncommon event for most people with or without primary open-angle glaucoma (POAG). Reduced OPP is emerging as a significant risk factor for glaucoma. Dr Varma reviews the data supporting this association.

Ocular Perfusion Pressure and Glaucoma: The Evidence

Dr Varma: Five major epidemiologic studies have provided data on the relationship between BP, OPP, IOP, and glaucoma. Four of these studies (Baltimore Eye Survey, Egna-Neumarkt Study, Proyecto VER, Los Angeles Latino Eye Study) were cross-sectional studies,¹⁻⁴ while the fifth (Barbados Eye Study) was a prospective, longitudinal study.⁵ Key design features and findings of these studies are summarized in Table 2.

The Baltimore Eye Survey was a cross-sectional study of persons of European and African ancestry in Baltimore, Maryland. The relevant finding from this study was that lower OPP was strongly associated with a higher prevalence of POAG. In fact, patients in the lowest category of DPP (<30 mm Hg) had a 6-fold higher risk for having glaucoma compared with those whose DPP was >50 mm Hg.¹

Table 2. Summary of Epidemiologic Studies Linking Diastolic Perfusion Pressure and Glaucoma¹⁻⁵

Study	Design	Participants	Glaucoma Risk From Low DPP vs Normal DPP
Baltimore Eye Survey	Cross-sectional	Non-Hispanic Whites and African Americans	6-fold
Egna-Neumarkt Study	Cross-sectional	Non-Hispanic Whites	2.5-fold
Proyecto VER	Cross-sectional	Hispanics	4-fold
Los Angeles Latino Eye Study	Cross-sectional	Latinos/Hispanics	1.9-fold
Barbados Eye Study	Longitudinal	Afro-Caribbeans	3.2-fold (4 years)

The Egna-Neumarkt Study was a cross-sectional study of persons of European ancestry in northern Italy. Persons with low DPP were at higher risk for having glaucoma. In this case, those with DPP <60 mm Hg had a 2.5-fold higher risk for glaucoma compared with those with DPP >76 mm Hg.²

Proyecto VER was a cross-sectional study of Hispanics in Nogales and Tucson, Arizona. This study found that people with DPP <50 mm Hg had a 4-fold higher risk for having glaucoma than those with DPP >80 mm Hg.³

The Los Angeles Latino Eye Study was a cross-sectional study of Latinos/Hispanics residing in Los Angeles, California. Compared with people whose DPP was between 51 and 60 mm Hg, those whose DPP was below 40 mm Hg had a 1.9-fold higher risk for glaucoma.⁴ In fact, low DPP, SPP, and MPP were all highly associated with the risk for glaucoma in this study (Figure 1).




Figure 1. Ocular perfusion pressure in the Los Angeles Latino Eye Study.⁴

Republished with permission from *Investigative Ophthalmology & Visual Science*, from Los Angeles Latino Eye Study Group. Blood pressure, perfusion pressure, and open-angle glaucoma: the Los Angeles Latino Eye Study, Memarzadeh F et al, 51(6), 2010.

In contrast to these 4 studies, the Barbados Eye Study was a prospective, longitudinal study of predominantly Afro-Caribbeans on the island of Barbados in the eastern Caribbean Ocean. Participants were enrolled in a cross-sectional prevalence study similar to the ones described above, but were reexamined 4 and 9 years after enrollment. This study design provides insight into the risk for *developing* glaucoma, in contrast to cross-sectional studies that describe *preexisting* glaucoma. At 4 years, low MPP, SPP, and DPP were all associated with a higher risk (2.6- to 3.2-fold) for developing new glaucoma.⁵ At 9 years, all 3 perfusion pressures remained significantly associated with developing glaucoma.⁶

Dr Ritch: Blood pressure is highly variable. How was it characterized in the studies?

Dr Varma: In most of these studies, BP was measured at least twice at baseline in a sitting position, so the analyses did not rely on a single snapshot value.

Dr Liebmann: The theme throughout is that low OPP is a significant risk factor for glaucoma. The absolute numbers were a bit different in these studies, but the message is the same: Low DPP is a risk factor for glaucoma. Do these studies reveal a risk associated with elevated OPP?

Low DPP is a risk factor for glaucoma.

—Jeffrey Liebmann, MD

Dr Varma: The risk for glaucoma decreases as OPP increases, and it plateaus at the higher levels.

Dr Greenfield: Ocular perfusion pressure may be reduced in 2 clinical scenarios: when BP is low or when IOP is high. In these epidemiologic studies, do we know if OPP was reduced because of low BP or because of high IOP? This is an important point because if elevated IOP was the reason for the low OPP, then BP may be less relevant and the increased glaucoma risk could be attributable primarily to elevated IOP.

Dr Varma: In most of these studies, mean IOP was in the 'normal' range. Interestingly, in these studies and in other epidemiologic studies, half or more of the newly diagnosed open-angle glaucoma cases have IOP in the normal range. We often think of glaucoma as being a high-pressure disease. This is more myth than fact. The average untreated IOP of Hispanics newly diagnosed with glaucoma in the Los Angeles Latino Eye Study was 17 mm Hg, with only 18% of all eyes with glaucoma having an IOP greater than 21 mm Hg.⁷ The median IOP of all glaucomatous eyes in non-Hispanic Whites and African Americans in the Baltimore Eye Survey was 20 mm Hg, with 41% of all eyes having an IOP greater than 21 mm Hg.⁸ So we cannot entirely attribute IOPs greater than 21 mm Hg for this increased risk for glaucoma. The low BP is relevant.

We often think of glaucoma as being a high-pressure disease. This is more myth than fact.

—Rohit Varma, MD, MPH

Dr Weinreb: I find it fascinating and important that in the Barbados study, OPP was a much more powerful risk factor for glaucoma than was IOP. I wish we had information about nocturnal IOP and BP from these epidemiologic studies. At night, IOP goes up and BP—particularly diastolic BP—goes

down, so the DPP is dually affected. I wonder if nocturnal DPP is even more strongly associated with glaucoma risk than are daytime values.

I find it fascinating and important that in the Barbados study, OPP was a much more powerful risk factor for glaucoma than was IOP.

—Robert N. Weinreb, MD

Dr Gupta: Our concept of glaucoma is shifting from a disease of a single pressure—IOP—to a disease of multiple pressures. Ocular perfusion pressure is clearly an important factor in glaucoma. Other research points to a potential role for intracranial pressure (ICP). Glaucoma is more than just IOP.

Dr Weinreb: Dr Gupta has spent many years investigating the role of the cerebrovascular system in glaucoma. She provides us with an overview of her work.

Our concept of glaucoma is shifting from a disease of a single pressure—IOP—to a disease of multiple pressures.

—Neeru Gupta, MD, PhD, MBA

The Cerebrovascular System in Glaucoma

Dr Gupta: We tend to think of glaucoma as a primary eye disease. As such, ophthalmologists have sole responsibility for its management, and all treatment options are directed at the eye. A substantial body of research stretches this view, and considers glaucoma disease in the context of central nervous system degeneration. In fact, most of the neurovisual system resides within the white matter of the brain. Glaucoma is much more than a disease of the eye, with evidence that it is a neurodegenerative disorder of the central visual system. There is demonstrable atrophy of the lateral geniculate nucleus—the terminus for optic nerve axons—in glaucoma (Figure 2).^{9,10} This has been demonstrated in primates¹¹ as well as in humans,¹⁰ the latter both by magnetic resonance imaging (MRI) in vivo and in histological specimens taken postmortem.




Figure 2. Atrophy of the lateral geniculate nucleus associated with glaucoma (left image) compared with normal controls (right images).^{9,10}

Adapted from Gupta N et al. *Br J Ophthalmol.* 2006;90(6):674-678 and Gupta N et al. *Br J Ophthalmol.* 2009;93(1):56-60.

Glaucoma is much more than a disease of the eye, with evidence that it is a neurodegenerative disorder of the central visual system.

—Neeru Gupta, MD, PhD, MBA

Further, blood vessels of the lateral geniculate nucleus demonstrate oxidative damage when stained appropriately.¹² More posteriorly, the visual cortex also manifests damage in glaucoma compared with controls in both primate¹³ and human studies.⁹ Functional deficits can be demonstrated in humans with glaucoma by functional MRI, which reveals reduced levels of blood oxygen in areas of the visual cortex that correspond to known visual field defects.¹⁴

According to what we know about the vascular contributions to the central visual system, much of it lies in a watershed zone of the brain. Watershed zones are more vulnerable to hypoperfusion and ischemia. It is possible that under conditions of unstable perfusion, such as low BP, the visual system becomes even more susceptible to neural degeneration.




Figure 3. Vascular circulations of the brain, with the visual pathway falling within a watershed zone (outlined in red) between the anterior and posterior circulatory systems.

Image Courtesy of Yeni Yücel, MD, PhD

When the vascular supply to the brain is considered (Figure 3), the role of cerebrovascular factors in glaucoma are better appreciated. The branches of the carotid artery—anterior, middle, and posterior cerebral arteries—supply most of the front aspect of the brain and, via the ophthalmic artery, the eyes. The vertebral-basilar system supplies the rear aspect of the brain. These 2 circulations are connected through the circle of Willis. Between these 2 circulations is a segment of brain that is supplied by minor branches of these major vessels—and within this so-called watershed zone lie the optic tracts, the lateral geniculate nuclei, the optic radiations, and the visual cortex.

An anatomic configuration of the vascular circulations of the brain provides insight into the importance of OPP. When BP is low, these watershed zones are quite vulnerable to hypoperfusion and ischemia. It is possible that under conditions

According to what we know about the vascular contributions to the central visual system, much of it lies in a watershed zone of the brain. Watershed zones are more vulnerable to hypoperfusion and ischemia. It is possible that under conditions of unstable perfusion, such as low BP, the visual system becomes even more susceptible to neural degeneration.

—Neeru Gupta, MD, PhD, MBA

of unstable perfusion, ischemic insults to these tissues could contribute to the neurodegenerative changes seen throughout the visual system in glaucoma.¹⁵

Dr Ritch: This watershed zone could be endangered by impairment of either the cerebral or the vertebrobasilar system. Is there a known role for vertebrobasilar insufficiency in glaucoma?

Dr Gupta: To my knowledge, this has not been reported. However, anything that compromises the BP within the cerebrovascular arterial system would affect both cerebral and ocular perfusion pressure. Visual structures in the watershed areas of the brain would be particularly more susceptible to global hypoperfusion.

Dr Weinreb: Hypoperfusion of the optic nerve may play a role in the development of glaucoma; it also is thought to be the basis of acute anterior ischemic optic neuropathy (AION). Could these 2 entities differ in terms of the vascular beds affected? For example, could AION be related to ischemia within the anterior circulation of the optic nerve and glaucoma to the more posterior vascular beds?

Dr Greenfield: I find it intriguing that while there are many well-established systemic disorders of chronic ischemia—such as congestive heart failure, ischemic heart disease, chronic ischemic dementia, and chronic ischemic renal disease—we have not characterized a chronic ischemic optic neuropathy. Perhaps that condition is glaucoma.

Dr Varma: Tools under development—such as optical coherence tomographic (OCT) angiography—may be able to provide insight into these issues. This technology has the potential to noninvasively image at the level of the capillaries and may provide functional data on blood flow. With that information, perhaps we will then better understand the relative contributions of IOP and blood flow to glaucomatous optic nerve damage.

Dr Liebmann: As we have said, there are many vascular risk factors associated with glaucoma, among them, potentially, cerebral hypoperfusion. This raises an interesting question: If glaucoma can be a manifestation of cerebral hypoperfusion, should we be alerting glaucoma patients and their internists to be alert for signs of cerebral hypoperfusion? Is there a cerebrovascular workup that should be undertaken for glaucoma patients?

Dr Ritch: This may be a reasonable approach. But in our health care system, it is impractical to expect all glaucoma patients to undergo imaging with MRI or even magnetic resonance angiography. Many internists with whom I work remain unconvinced that BP is relevant in glaucoma—thus, it would be difficult to convince them to conduct a more extensive workup. On the other hand, can we formulate an equation for intracranial perfusion pressure similar to that for OPP? If we consider that the driving force of blood pressure to the eye and brain are similar, would it be a legitimate analogy to substitute ICP for IOP in the equation used for deriving mean OPP and thus have an estimate for mean intracranial perfusion pressure? We still have no simple and reliable means of noninvasive measurement of ICP, but several groups are working on developing one.

Dr Liebmann: Consider starting on a smaller scale. At a bare minimum, let us ask patients if they know their BP. Currently,

when taking a medical history, we ask about hypertension and medications. Should we also ask about *hypotension*? Or we could go a step further. Perhaps all our glaucoma patients should undergo BP measurement in our offices. Knowing their BP allows us to calculate their OPP, which then aids us in risk assessment. If we detect low BP, it might be prudent to notify the patient's internist and let him or her decide what, if any, workup might be warranted. Likewise, perhaps the internist should consider referring patients with low BP for glaucoma screening.

Dr Weinreb: At this point, it seems appropriate to move on to consideration of the clinical applications of OPP. Dr Greenfield presents a framework for this discussion.

Ocular Perfusion Pressure in Current Clinical Practice

Dr Greenfield: We have reviewed the definition of OPP, the evidence linking it to the development of glaucoma as a risk factor, and have learned of some interesting research findings that may reveal a potential mechanism within the central nervous system by which low BP might be causally related to the development of glaucoma.

Several key questions remain. Is the value of OPP firmly enough established that we should be routinely assessing OPP in our glaucoma patients? Or, if not in all our patients, are there subsets of our patients in whom knowledge of OPP might be clinically relevant? If so, how should we best characterize OPP?

Dr Weinreb: Let us address these questions individually. Firstly, should we routinely measure OPP in all our glaucoma patients?

Dr Greenfield: In an ideal world, yes, we would, because OPP measurement is noninvasive, inexpensive, and easy to obtain, and provides clinicians with data to more fully assess not only patients' glaucoma risk, but also their overall systemic health. In a busy clinical practice, however, in which a clinician sees 40 to 50 patients per day, the added time necessary to obtain BP readings and to calculate and record OPP will cost money and reduce clinical efficiency, and will likely not be effective for treatment planning in most patients.

OPP measurement is noninvasive, inexpensive, and easy to obtain, and provides clinicians with data to more fully assess not only patients' glaucoma risk, but also their overall systemic health.

—David S. Greenfield, MD

Dr Ritch: I agree. For instance, if I discovered a low OPP in a patient whose glaucoma has remained stable for many years, I might notify the internist of this finding, but I would be unlikely to change the patient's glaucoma management to try to further lower IOP by 1 or 3 mm Hg; but if the glaucoma was not stable, I would obtain 24-hour blood pressure measurements, which we do routinely, and consider salt loading if nocturnal OPP was reduced. There are many risk factors which make me consider glaucoma occurring at normal IOP to be a nocturnal disease.

Dr Weinreb: But, secondly, is it correct to assume that there are subsets of patients in whom knowledge of OPP might be beneficial?

There are many risk factors which make me consider glaucoma occurring at normal IOP to be a nocturnal disease.

—Robert Ritch, MD

Dr Greenfield: You are correct in your assumption. Measurement of OPP would be beneficial (Table 3) in POAG patients with IOP in the normal range. We can agree or disagree as to whether normal-tension glaucoma is a separate clinical entity or is merely POAG occurring within the normal range of IOP. But in 2 major clinical trials of patients with glaucoma and IOP in the normal range, vascular risk factors were found to be the strongest predictors of progression. The Collaborative Normal-Tension Glaucoma Study identified optic disc hemorrhage and migraine as predictive factors for progression,¹⁶ and the Low-Pressure Glaucoma Treatment Study (LoGTS) identified reduced mean OPP and the use of systemic antihypertensive medication as risk factors for visual field progression.¹⁷

Table 3. Patient Subgroups In Which to Consider the Value of Assessing Ocular Perfusion Pressure

• Normal-tension glaucoma
• Eyes with optic disc hemorrhage
• Patients with progression at low IOP
• History of low BP, multiple systemic antihypertensives, symptoms of orthostasis
• Patients with nocturnal hypotension

Patients with optic disc hemorrhage might benefit from OPP assessment. Disc hemorrhages can occur in both normal-tension and high-tension glaucoma and the exact mechanism by which they appear remains elusive. In LoGTS, low mean OPP as well as low mean systolic BP, migraine headache, and use of systemic beta-blockers were all associated with the development of optic disc hemorrhage.¹⁸

Patients whose glaucoma is progressing at what appears to be an adequately low IOP level also may benefit from OPP assessment. Charlson and colleagues conducted a study in which a reduction in mean arterial pressure from daytime to nighttime was found to be a significant predictor of visual field progression in such patients.¹⁹

Finally, patients who report a history of low BP, who are using multiple systemic antihypertensive medications, or who have symptoms of orthostatic hypotension, may benefit from OPP assessment.

Dr Weinreb: The third key question is, How should we best characterize OPP? Which of the many ways to measure OPP should we use? Mean? Systolic? Diastolic? And is a single random measurement adequate? Or should we assess OPP at multiple time points, such as a diurnal curve? Or should we obtain 24-hour IOP and BP monitoring to ensure adequate characterization of the important nocturnal period?

Dr Greenfield: All valid options. A single BP and IOP measurement allows a quick snapshot, but because both BP and IOP vary widely, it will not be a complete characterization. This is the same challenge we face with IOP. If there is particular

concern that low OPP may be contributing to glaucoma progression, a single-day diurnal assessment might be worthwhile, or a modified diurnal assessment can be constructed by seeing the patient at different times of the day on different visits. Certainly 24-hour ambulatory BP monitoring is the most robust approach and will reveal “nocturnal dippers” whose BP bottoms out at night, but such monitoring is both cumbersome and expensive, and we do not yet have satisfactory 24-hour IOP monitoring tools with which to characterize 24-hour OPP.

Dr Weinreb: The fundamental questions are the following: Do we have adequate evidence to justify the clinical use of OPP in glaucoma management? Do we know enough about OPP to know what to do with the information we obtain? Is the strength of evidence strong enough to recommend that OPP be made a routine part of glaucoma management?

Dr Varma: I believe that with the evidence we have to date, it is reasonable to obtain an assessment of BP in our patients with glaucoma. And, based on the strength of evidence from the studies to date, I would pay more attention to DPP.

Dr Weinreb: And what would we do with this information? Are there interventions to improve OPP? And is there any evidence that improving OPP has any beneficial effect on glaucoma?

I believe that with the evidence we have to date, it is reasonable to obtain an assessment of BP in our patients with glaucoma.

—Rohit Varma, MD, MPH

Dr Greenfield: In my opinion, identifying a low OPP in a patient progressing at low IOP represents a potentially actionable scenario. The data reported by Charlson and colleagues¹⁹ indirectly suggests that patients with glaucoma progression using systemic antihypertensive agents may benefit from adjusting the dose or time of antihypertensive administration to avoid low mean arterial pressure, particularly during the nocturnal period.

My colleagues and I recently published a paper showing that the visual field can improve in the short term following surgical IOP reduction, and that the magnitude of the visual field improvement is significantly associated with the mean OPP.²⁰ We prospectively compared a group of 30 eyes that had surgical IOP lowering via trabeculectomy or glaucoma drainage device implantation with a group of 41 control eyes that had stable IOP during the same time period. Following IOP reduction on average from 18 to 10 mm Hg, a significantly greater number of visual field points improved in the surgical group than in the control group. This improvement was not correlated with the change in IOP, but was significantly related to improvement in postoperative mean OPP. Our study is consistent with other reports of visual field improvement after IOP reduction^{21,22} and provides indirect support that OPP may be related to both visual field progression and visual field improvement.

Dr Weinreb: On the basis of the foregoing discussion and in light of the data presented, is it reasonable to propose that OPP is potentially a new modifiable risk factor for glaucoma care?

Dr Greenfield: In cross-sectional and longitudinal studies, we have seen that OPP is an important risk factor for glaucoma

We should consider measuring OPP in selected patients, particularly those in whom glaucoma progression is occurring at low levels of IOP, and/or patients who develop optic disc hemorrhage.

—David S. Greenfield, MD

onset and glaucoma progression. Therefore, OPP might be a potentially modifiable risk factor. We know that at present IOP is the only modifiable risk factor. Intraocular pressure and diastolic BP contribute more from a mathematical calculation to OPP than does systolic BP, and clinicians need to pay attention to the various factors that influence OPP. We should consider measuring OPP in selected patients, particularly those in whom glaucoma progression is occurring at low levels of IOP, and/or patients who develop optic disc hemorrhage.

Dr Weinreb: If OPP is a modifiable risk factor, how might we modify it?

Dr Ritch: The first step is to review a patient's medical and medication history. Patients with systemic hypertension may be overmedicated, with their diastolic BP dropping lower than necessary. Most important, in my view, is the nocturnal diastolic pressure, which is lowered by the patient's taking of BP medications at bedtime. Just as IOP has a 24-hour fluctuation, so does BP, which may be high during the day but normal nocturnally, and taking BP medication in the evening can produce a significant drop in nocturnal mean arterial pressure. Being mindful of the nocturnal dip in diastolic BP, I would communicate with the internist or cardiologist and ask if treatment can be shifted from the evening to the morning to best protect against nocturnal dips. Topical beta-blockers may also lower BP at night in some patients²³ and measuring 24-hour BP with and without topical beta-blockers may provide useful information. If the patient is dependent on beta-blockers for IOP control, this must be taken into account.

Patients with systemic hypertension may be overmedicated, with their diastolic BP dropping lower than necessary.... Being mindful of the nocturnal dip in diastolic BP, I would communicate with the internist or cardiologist and ask if treatment can be shifted from the evening to the morning to best protect against nocturnal dips.

—Robert Ritch, MD

Dr Varma: Consider a patient who is not being overmedicated, or in whom the current antihypertensive regimen cannot be reduced. Is there any value to salt addition as a means of preventing diastolic BP from bottoming out during the night?

Dr Ritch: Although the evidence is limited, we have recommended salt loading to some patients in order to increase OPP. We initially start with salty snacks, such as pretzels and potato chips, then move to V8 juice, which has a high sodium content, or salt tablets. We have had patients whose nocturnal dipping did improve significantly. Granted, these examples are from individual case reports. There are no data from epidemiologic studies or trials to support salt loading in this setting.

Dr Gupta: I agree with you. We all have patients who are progressing at low IOP and who are nocturnal dippers. Twenty-four-hour BP monitoring may help to identify these patients. Salty snacks or beverages at night may help, although the evidence is anecdotal.

Case From the Files of Robert Ritch, MD

Salt loading may or may not be successful at elevating nocturnal BP. A case in point is a patient who was extremely difficult to control. This was a 50-year-old white woman with -7.00 diopters of myopia and recurrent disc hemorrhages with progression of her glaucoma with IOPs in the low to mid teens. She had lamina cribrosa defects on enhanced depth imaging-OCT, and polysomnography was negative for obstructive sleep apnea. Twenty-four-hour BP measurement showed extensive nocturnal dipping. A repeat measurement showed improvement, but recurrent disc hemorrhages prompted a third measurement, which showed regression and an apparent loss of continued effect of salt loading (Figures 4A, 4B, 4C). She eventually underwent trabeculectomy OU.




Figure 4. Patient 1 BP monitoring. A) August 2012—12-hour BP monitoring: No salt loading; B) May 2013—12-hour BP monitoring: Salt loading; C) November 2014—24-hour BP monitoring: Diurnal curve.

Images Courtesy of Robert Ritch, MD

This is in contrast to another patient who had significant improvement after salt loading with cessation of progression to date, although repeat testing has not since been performed (Figures 5A, 5B).




Figure 5. Patient 2 BP monitoring. A) 24-hour BP: No salt; B) 24-hour BP: Salt loading.

Images Courtesy of Robert Ritch, MD

Summary and Conclusions

The concept of OPP as the balance of 2 opposing forces—BP and IOP—has been offered. The evidence linking OPP to glaucoma has been reviewed. A biologically plausible mechanism by which central nervous system hypoperfusion may predispose to glaucoma has been presented. Further, we have described the notion of OPP as a modifiable risk factor for glaucoma progression independent of IOP reduction. In summary, the panel has drawn up a series of points to consider regarding the role of OPP in glaucoma.

Key Learning Points

- Many vascular risk factors have been associated with glaucoma
 - Low diastolic BP
 - Reduced nocturnal BP
 - Decreased OPP
- Several other vascular factors should be considered in select glaucoma patients
 - Migraine
 - Raynaud phenomenon
 - Hypertension (particularly when treated)
- OPP is an established risk factor for glaucoma onset and progression
- OPP may be a modifiable risk factor and treatment target in glaucoma
- IOP and diastolic BP contribute more to OPP than does systolic BP
- Many factors influence OPP
- Measurement of OPP in select patients (those with low IOP, especially those who are progressing, and those with disc hemorrhages) should be considered
- 24-hour IOP and BP measurements will provide more robust assessments than single daytime measurements

References

1. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. *Arch Ophthalmol*. 1995;113(2):216-221.
2. Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. *Ophthalmology*. 2000;107(7):1287-1293.
3. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. *Arch Ophthalmol*. 2001;119(12):1819-1826.
4. Memarzadeh F, Ying-Lai M, Chung J, Azen SP, Varma R; Los Angeles Latino Eye Study Group. Blood pressure, perfusion pressure, and open-angle glaucoma: the Los Angeles Latino Eye Study. *Invest Ophthalmol Vis Sci*. 2010;51(6):2872-2877.
5. Leske MC, Wu SY, Nemesure B, Hennis A. Incident open-angle glaucoma and blood pressure. *Arch Ophthalmol*. 2002;120(7):954-959.
6. Leske MC, Wu SY, Hennis A, Honkanen R, Nemesure B; BESs Study Group. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. *Ophthalmology*. 2008;115(1):85-93.
7. Varma R, Ying-Lai M, Francis BA, et al; Los Angeles Latino Eye Study Group. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. *Ophthalmology*. 2004;111(8):1439-1448.
8. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. *Arch Ophthalmol*. 1991;109(8):1090-1095.
9. Gupta N, Ang LC, Noël de Tilly L, Bidaisee L, Yücel YH. Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus, and visual cortex. *Br J Ophthalmol*. 2006;90(6):674-678.
10. Gupta N, Greenberg G, de Tilly LN, Gray B, Polemiotis M, Yücel YH. Atrophy of the lateral geniculate nucleus in human glaucoma detected by magnetic resonance imaging. *Br J Ophthalmol*. 2009;93(1):56-60.
11. Yücel YH, Zhang Q, Gupta N, Kaufman PL, Weinreb RN. Loss of neurons in magnocellular and parvocellular layers of the lateral geniculate nucleus in glaucoma. *Arch Ophthalmol*. 2000;118(3):378-384.
12. Luthra A, Gupta N, Kaufman PL, Weinreb RN, Yücel YH. Oxidative injury by peroxynitrite in neural and vascular tissue of the lateral geniculate nucleus in experimental glaucoma. *Exp Eye Res*. 2005;80(1):43-49.
13. Yücel YH, Zhang Q, Weinreb RN, Kaufman PL, Gupta N. Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. *Prog Retin Eye Res*. 2003;22(4):465-481.
14. Duncan RO, Sample PA, Weinreb RN, Bowd C, Zangwill LM. Retinotopic organization of primary visual cortex in glaucoma: Comparing fMRI measurements of cortical function with visual field loss. *Prog Retin Eye Res*. 2007;26(1):38-56.
15. Yücel YH, Gupta N. Paying attention to the cerebrovascular system in glaucoma. *Can J Ophthalmol*. 2008;43(3):342-346.
16. Drance S, Anderson DR, Schulzer M; Collaborative Normal-Tension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. *Am J Ophthalmol*. 2001;131(6):699-708.
17. De Moraes CG, Liebmann JM, Greenfield DS, Gardiner SK, Ritch R, Krupin T; Low-pressure Glaucoma Treatment Study Group. Risk factors for visual field progression in the low-pressure glaucoma treatment study. *Am J Ophthalmol*. 2012;154(4):702-711.
18. Furlanetto RL, De Moraes CG, Teng CC, et al; Low-Pressure Glaucoma Treatment Study Group. Risk factors for optic disc hemorrhage in the low-pressure glaucoma treatment study. *Am J Ophthalmol*. 2014;157(5):945-952.
19. Charlson ME, de Moraes CG, Link A, et al. Nocturnal systemic hypotension increases the risk of glaucoma progression. *Ophthalmology*. 2014;121(10):2004-2012.
20. Wright TM, Goharian I, Gardiner SK, Sehi M, Greenfield DS. Short-term enhancement of visual field sensitivity in glaucomatous eyes following surgical intraocular pressure reduction. *Am J Ophthalmol*. 2015;159(2):378-385.e1.
21. Spaeth GL. The effect of change in intraocular pressure on the natural history of glaucoma: lowering intraocular pressure in glaucoma can result in improvement of visual fields. *Trans Ophthalmol Soc U K*. 1985;104(Pt 3):256-264.
22. Musch DC, Gillespie BW, Palmberg PF, Spaeth G, Niziol LM, Lichter PR. Visual field improvement in the Collaborative Initial Glaucoma Treatment Study. *Am J Ophthalmol*. 2014;158(1):96-104.
23. Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension. *Am J Ophthalmol*. 1999;128(3):301-309.

CME Post Test Questions

To obtain *AMA PRA Category 1 Credit™* for this activity, complete the CME Post Test by writing the best answer to each question in the Answer Box located on the Activity Evaluation/Credit Request form on the following page. Alternatively, you can complete the CME Post Test online at <http://tinyurl.com/OPPinGlaucoma>.

See detailed instructions at **To Obtain *AMA PRA Category 1 Credit™*** on page 2.

- Ocular perfusion pressure _____.
 - Is the pressure at which blood leaves the eye
 - Is constant throughout the day
 - Is more dependent on diastolic than systolic BP
 - Is potentially contributory to glaucoma damage when it is above 75 mm Hg
- The evidence linking OPP to glaucoma has been observed in _____.
 - Whites
 - African Americans
 - Hispanics
 - All the above
- Which measure of OPP has been most strongly linked to glaucoma risk?
 - Mean OPP
 - Systolic OPP
 - Diastolic OPP
 - Mean arterial pressure
- Compared with DPP in the normal range, the lowest levels of DPP are generally associated with a _____ risk for glaucoma.
 - 1- to 2-fold
 - 2- to 6-fold
 - 8- to 10-fold
 - 15- to 20-fold
- Within the central nervous system, the _____ has not been shown to be damaged in glaucoma.
 - Lateral geniculate nucleus
 - Blood vessels within the lateral geniculate nucleus
 - Visual cortex
 - Cerebellum
- Why might the central visual pathways be susceptible to damage in the setting of hypoperfusion?
 - There is not enough cerebrospinal fluid to nourish the brain tissue
 - Most of the visual pathway lies within a vascular watershed area in the brain, which is particularly vulnerable to ischemic damage in the setting of hypoperfusion
 - The visual pathway is made up of gray matter that is hypersensitive to hypoperfusion
 - The axons of the optic nerve do not extend past the lateral geniculate nucleus
- Nocturnal OPP is often low both because the BP is low and because _____.
 - The patient is asleep
 - Perfusion is reduced in the dark
 - IOP is highest at night
 - The heart rate is low at night
- Which of the following patients would least likely benefit from OPP assessment?
 - A patient with progressive POAG
 - A glaucoma patient with a disc hemorrhage
 - A patient on 3 antihypertensive medications
 - A patient with low IOP and stable visual fields
- The strength of evidence for modifying OPP in glaucoma patients is at the level of _____.
 - Meta-analysis
 - Randomized clinical trials
 - Epidemiologic studies
 - Case reports
- In which of the following patient scenarios would measuring OPP be of greatest clinical value?
 - A well-controlled and stable patient
 - A patient with elevated IOP who is progressing
 - A patient with low IOP who is progressing
 - A patient with low IOP who is stable

Activity Evaluation/Credit Request

The Role of Ocular Perfusion Pressure in Glaucoma

Original Release Date: November 1, 2015 | Last Review Date: September 22, 2015 | Expiration Date: November 30, 2016

To receive *AMA PRA Category 1 Credit™*, you must complete this **Evaluation** form and the **Post Test**. Record your answers to the **Post Test** in the **Answer Box** located below. Mail or Fax this completed page to **New York Eye and Ear Infirmary of Mount Sinai–ICME**, 310 East 14th Street, New York, NY 10003 (Fax: 212-353-5703). Your comments help us to determine the extent to which this educational activity has met its stated objectives, assess future educational needs, and create timely and pertinent future activities. Please provide all the requested information below. This ensures that your certificate is filled out correctly and is mailed to the proper address. It also enables us to contact you about future CME activities. Please print clearly or type. Illegible submissions cannot be processed.

PARTICIPANT INFORMATION (Please Print) Home Office

Last Name _____ First Name _____

Specialty _____ Degree MD DO OD PharmD RPh NP RN PA Other _____

Institution _____

Street Address _____

City _____ State _____ ZIP Code _____ Country _____

Phone _____ Fax _____ E-mail _____

Please note: We do not sell or share e-mail addresses. They are used strictly for conducting post-activity follow-up surveys to assess the impact of this educational activity on your practice.

Learner Disclosure: To ensure compliance with the US Centers for Medicare and Medicaid Services regarding gifts to physicians, **New York Eye and Ear Infirmary of Mount Sinai** Institute for CME requires that you disclose whether or not you have any financial, referral, and/or other relationship with our institution. **CME certificates cannot be awarded unless you answer this question.** For additional information, please call NYEE ICME at 212-979-4383. Thank you.

Yes No I and/or my family member have a financial relationship with **New York Eye and Ear Infirmary of Mount Sinai** and/or refer Medicare/Medicaid patients to it.

I certify that I have participated in the entire activity and claim **1.5 AMA PRA Category 1 Credits™**.

Signature Required _____ Date Completed _____

OUTCOMES MEASUREMENT

Yes No Did you perceive any commercial bias in any part of this activity? **IMPORTANT! If you answered "Yes," we urge you to be specific about where the bias occurred so we can address the perceived bias with the contributor and/or in the subject matter in future activities.**

Circle the number that best reflects your opinion on the degree to which the following learning objectives were met:
5 = Strongly Agree 4 = Agree 3 = Neutral 2 = Disagree 1 = Strongly Disagree

Upon completion of this activity, I am better able to:

- | | | | | | |
|--|---|---|---|---|---|
| • Outline the role of ocular perfusion pressure as a risk factor for glaucoma | 5 | 4 | 3 | 2 | 1 |
| • Describe the assessment of ocular perfusion pressure in patients with glaucoma | 5 | 4 | 3 | 2 | 1 |

1. Please list one or more things, if any, you learned from participating in this educational activity that you did not already know. _____

2. As a result of the knowledge gained in this educational activity, how likely are you to implement changes in your practice?
4=definitely will implement changes 3=likely will implement changes 2=likely will not implement any changes 1=definitely will not make any changes

	4	3	2	1
--	---	---	---	---

Please describe the change(s) you plan to make: _____

3. Related to what you learned in this activity, what barriers to implementing these changes or achieving better patient outcomes do you face?

4. Please check the Core Competencies (as defined by the Accreditation Council for Graduate Medical Education) that were enhanced for you through participation in this activity.

<input type="checkbox"/> Patient Care	<input type="checkbox"/> Practice-Based Learning and Improvement	<input type="checkbox"/> Professionalism
<input type="checkbox"/> Medical Knowledge	<input type="checkbox"/> Interpersonal and Communication Skills	<input type="checkbox"/> Systems-Based Practice

5. What other topics would you like to see covered in future CME programs? _____

ADDITIONAL COMMENTS

POST TEST ANSWER BOX

1	2	3	4	5	6	7	8	9	10

